Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Chongkundang Holdings Corp is a prominent holding company based in South Korea. Its primary function is to manage and oversee its various subsidiary companies, which operate predominantly in the pharmaceutical and health-related sectors. As a holding entity, Chongkundang Holdings Corp provides strategic guidance and financial oversight to its subsidiaries, facilitating operational efficiency and growth. The company's influence extends into diverse industries, often focusing on innovative healthcare solutions, manufacturing of pharmaceuticals, and distribution of medical supplies. This wide-ranging involvement makes Chongkundang Holdings Corp significant in the South Korean financial market, as it aligns with the growing global demand for medical and healthcare advancements. Its role as a holding company positions it as a cornerstone for fostering innovation within its subsidiaries, at the same time impacting broader industry standards and practices.
€39,750.00
+€750.00 (+1.92%)
Live · 05:26 PM
Operating margin is thin at 6.08%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue growth slowed to 0.1%, essentially flat. This is a business that needs a catalyst.
At 6512x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Net debt of ₩423.71B represents 23.0x FCF, leverage limits flexibility.
6512.2x earnings, 10443.7x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩952.66B
▲ +0.1% YoY
Net Income (TTM)
₩64.37B
▲ +34.8% YoY
Op. Margin
6.94%
▲ +2.4pp YoY
ROIC
3.49%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩33.47B
▲ +27160.4% YoY
Op. Cash Flow (TTM)
₩107.56B
▲ +163.1% YoY
Net Debt
₩423.71B
Cash & Equiv.
₩117.10B
3Y CAGR: +1.8%
Continue Research
At a P/E of 6,512.2 and a price-to-free-cash-flow of 10,443.7, Chongkundang Holdings (001630.XKRX) trades below a two-stage DCF intrinsic value of about KRW 254,479.82 per share, so at KRW 39,750.00 the stock looks undervalued (540.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Chongkundang Holdings scores 46/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 254,479.82 per share for 001630.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 190,859.86. At today's KRW 39,750.00, that puts the stock about 540.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Chongkundang Holdings scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 6.9% operating margin and a 3.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 001630.XKRX currently trades below its estimated intrinsic value and scores 46/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.